Basilar artery occlusion management: An international survey of middle versus high-income countries
Background and Purpose Two early basilar artery occlusion (BAO) randomized controlled trials (RCTs) did not establish the superiority of endovascular thrombectomy (EVT) over medical management. Yet many providers continued to recommend EVT. The goal of the present article is to compare physicians’ diagnostic and management strategies of BAO among middle-income and high-income countries (MICs and HICs, respectively). Methods We conducted an international survey from January to March 2022 regarding management strategies in acute BAO, to examine clinical and imaging parameters influencing clinician management of patients with BAO. We compared responses between physicians from HIC and MIC. Results Among the 1245 respondents from 73 countries, 799 (64.2%) were from HIC, with the remaining 393 (31.6%) from MIC. Most respondents perceived that EVT was superior to medical management for acute BAO, but more so in respondents from HIC (98.0% vs. 94.2%, p < 0.01). MIC respondents were more likely to believe further RCTs were warranted (91.6% vs. 74.0%, p < 0.01) and were more likely to find it acceptable to enroll any patient who met a trial’s criteria in the standard medical treatment arm (58.8% vs. 38.5%, p < 0.01).Conclusions Conclusions In an area where clinical equipoise was called into question despite the lack of RCT evidence, we found that respondents from MIC were more likely to express willingness to enroll patients with BAO in an RCT than their HIC counterparts.
Publication Details
- Journal
- heiDOK (Heidelberg University)
- Published
- 2025-01-01
- DOI
- https://doi.org/10.11588/heidok.00036128
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- CSL Behring
- Joachim Herz Stiftung
- Stryker
- Amarin Corporation
- Amicus Therapeutics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Daiichi-Sankyo
- Novo Nordisk
- Schweizerische Akademie der Medizinischen Wissenschaften
- H. Lundbeck A/S
- Allergan
- Daiichi Sankyo Europe